Opinion|Videos|May 9, 2025
Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC
Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Overall Survival Data from MARIPOSA Trial
Key Themes:
- Significant Survival Improvement: Analysis of the MARIPOSA trial showing amivantamab plus lazertinib leads to improved progression-free survival and overall survival
- Statistical Impact: Overall survival hazard ratio of 0.75 with projected median overall survival exceeding 1 year
- Comparison Considerations: Discussion of MARIPOSA vs FLAURA2 trial designs and outcomes
Notable Insights:
- Dr Dietrich: Called the 12-plus-months overall survival improvement “very refreshing” and noted the “relatively flat trajectory as we move out further on the curve,” indicating durable benefit. He stated, “Breaking through 4 years of overall survival is one thing and...5-year landmark improvements...is also very, very significant.”
- Dr Piotrowska: Emphasized caution when comparing trials, noting that MARIPOSA had “no crossover allowed” while FLAURA2 patients could access chemotherapy in later lines of treatment, making direct comparison of survival outcomes challenging.
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Issues CRL to 177Lu-Edotreotide for GEP-NETs
2
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
3
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
4
Relapsed/Refractory Multiple Myeloma: Applying Real-World Evidence to CAR T-Cell Therapy
5